Prognostische waarde van PSMA PET/CT in het voorspellen van de biochemisch recidiefvrije overleving na radicale prostatectomie in miN0-patiënten

doi:10.1007/s13629-025-00485-1

Prognostische waarde van PSMA PET/CT in het voorspellen van de biochemisch recidiefvrije overleving na radicale prostatectomie in miN0-patiënten

Translated title of the contribution: Prognostic value of PSMA PET/CT-based in predicting biochemical recurrence after radical prostatectomy in miN0 patients

Department of Radiotherapy - residents

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In this international multicenter retrospective study, we analyzed 476 patients with localized or locally advanced prostate cancer without suspicious lymph node involvement (miN0). All patients were staged with PSMA PET/CT and MRI before radical prostatectomy (2016–2023). We assessed the added value of PSMA PET/CT local staging alongside MRI in predicting biochemical recurrence free survival (BRFS). A minimum follow-up of 6 months was required. Multivariable Cox-regression showed PSA, biopsy ISUP GG, MRI T‑stage and PSMA PET T‑stage as independent predictors of BRFS. The 2‑year BRFS was 19% in patients with T3b disease on both MRI and PSMA PET, versus 58% with T3b only on MRI (p = 0.03). The study supports that PSMA PET/CT-based local staging adds prognostic value beyond MRI alone.

Translated title of the contribution	Prognostic value of PSMA PET/CT-based in predicting biochemical recurrence after radical prostatectomy in miN0 patients
Original language	Dutch
Pages (from-to)	98-107
Number of pages	10
Journal	Tijdschrift voor Urologie
Volume	16
Issue number	5
Early online date	2025
DOIs	https://doi.org/10.1007/s13629-025-00485-1
Publication status	Published - Aug 2026

Keywords

Biochemical recurrence-free survival
MRI
Prostate cancer
PSMA PET/CT

Access to Document

10.1007/s13629-025-00485-1Licence: CC BY

s13629-025-00485-1Final published version, 645 KBLicence: CC BY

Cite this

@article{dcc2c3382405454aa55c25ab4b33fb1a,

title = "Prognostische waarde van PSMA PET/CT in het voorspellen van de biochemisch recidiefvrije overleving na radicale prostatectomie in miN0-pati{\"e}nten",

abstract = "In this international multicenter retrospective study, we analyzed 476 patients with localized or locally advanced prostate cancer without suspicious lymph node involvement (miN0). All patients were staged with PSMA PET/CT and MRI before radical prostatectomy (2016{\textendash}2023). We assessed the added value of PSMA PET/CT local staging alongside MRI in predicting biochemical recurrence free survival (BRFS). A minimum follow-up of 6 months was required. Multivariable Cox-regression showed PSA, biopsy ISUP GG, MRI T‑stage and PSMA PET T‑stage as independent predictors of BRFS. The 2‑year BRFS was 19\% in patients with T3b disease on both MRI and PSMA PET, versus 58\% with T3b only on MRI (p = 0.03). The study supports that PSMA PET/CT-based local staging adds prognostic value beyond MRI alone.",

keywords = "Biochemical recurrence-free survival, MRI, Prostate cancer, PSMA PET/CT",

author = "Vera Sweere and Slot, \{Alexandra Bruins\} and Rick Hermsen and Heetman, \{Joris G.\} and Lieke Wever and Jules Lavalaye and Maarten Vinken and Bahler, \{Clinton D.\} and Mark Tann and Claudia Kesch and Tugce Telli and Fendler, \{Wolfgang P.\} and Chiu, \{Peter Ka Fung\} and Fabio Zattoni and Laura Evangelista and Francesco Ceci and Marcin Miszczyk and Pawel Rajwa and Francesco Barletta and Alberto Briganti and Francesco Montorsi and Giorgio Gandaglia and \{Van Basten\}, \{Jean Paul A.\} and \{Van Melick\}, \{Harm H.E.\} and \{Van den Bergh\}, \{Roderick C.N.\} and Giancarlo Marra and Scheltema, \{Matthijs J.\} and Soeterik, \{Timo F.W.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2026",

month = aug,

doi = "10.1007/s13629-025-00485-1",

language = "Dutch",

volume = "16",

pages = "98--107",

journal = "Tijdschrift voor Urologie",

issn = "2211-3037",

publisher = "Springer Science + Business Media",

number = "5",

}

TY - JOUR

T1 - Prognostische waarde van PSMA PET/CT in het voorspellen van de biochemisch recidiefvrije overleving na radicale prostatectomie in miN0-patiënten

AU - Sweere, Vera

AU - Slot, Alexandra Bruins

AU - Hermsen, Rick

AU - Heetman, Joris G.

AU - Wever, Lieke

AU - Lavalaye, Jules

AU - Vinken, Maarten

AU - Bahler, Clinton D.

AU - Tann, Mark

AU - Kesch, Claudia

AU - Telli, Tugce

AU - Fendler, Wolfgang P.

AU - Chiu, Peter Ka Fung

AU - Zattoni, Fabio

AU - Evangelista, Laura

AU - Ceci, Francesco

AU - Miszczyk, Marcin

AU - Rajwa, Pawel

AU - Barletta, Francesco

AU - Briganti, Alberto

AU - Montorsi, Francesco

AU - Gandaglia, Giorgio

AU - Van Basten, Jean Paul A.

AU - Van Melick, Harm H.E.

AU - Van den Bergh, Roderick C.N.

AU - Marra, Giancarlo

AU - Scheltema, Matthijs J.

AU - Soeterik, Timo F.W.

PY - 2026/8

Y1 - 2026/8

N2 - In this international multicenter retrospective study, we analyzed 476 patients with localized or locally advanced prostate cancer without suspicious lymph node involvement (miN0). All patients were staged with PSMA PET/CT and MRI before radical prostatectomy (2016–2023). We assessed the added value of PSMA PET/CT local staging alongside MRI in predicting biochemical recurrence free survival (BRFS). A minimum follow-up of 6 months was required. Multivariable Cox-regression showed PSA, biopsy ISUP GG, MRI T‑stage and PSMA PET T‑stage as independent predictors of BRFS. The 2‑year BRFS was 19% in patients with T3b disease on both MRI and PSMA PET, versus 58% with T3b only on MRI (p = 0.03). The study supports that PSMA PET/CT-based local staging adds prognostic value beyond MRI alone.

AB - In this international multicenter retrospective study, we analyzed 476 patients with localized or locally advanced prostate cancer without suspicious lymph node involvement (miN0). All patients were staged with PSMA PET/CT and MRI before radical prostatectomy (2016–2023). We assessed the added value of PSMA PET/CT local staging alongside MRI in predicting biochemical recurrence free survival (BRFS). A minimum follow-up of 6 months was required. Multivariable Cox-regression showed PSA, biopsy ISUP GG, MRI T‑stage and PSMA PET T‑stage as independent predictors of BRFS. The 2‑year BRFS was 19% in patients with T3b disease on both MRI and PSMA PET, versus 58% with T3b only on MRI (p = 0.03). The study supports that PSMA PET/CT-based local staging adds prognostic value beyond MRI alone.

KW - Biochemical recurrence-free survival

KW - MRI

KW - Prostate cancer

KW - PSMA PET/CT

UR - https://www.scopus.com/pages/publications/105025152807

U2 - 10.1007/s13629-025-00485-1

DO - 10.1007/s13629-025-00485-1

M3 - Article

AN - SCOPUS:105025152807

SN - 2211-3037

VL - 16

SP - 98

EP - 107

JO - Tijdschrift voor Urologie

JF - Tijdschrift voor Urologie

IS - 5

ER -

Prognostische waarde van PSMA PET/CT in het voorspellen van de biochemisch recidiefvrije overleving na radicale prostatectomie in miN0-patiënten

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this